This article presents an analytic tool populated with data from published studies to illustrate the likely impacts of a switch from typical to atypical antipsychotic drugs over a 3-year period on individual, family, and societal outcomes for a US. schizophrenia population. Data taken from clinical trials and observational data studies are used. Changes in annual health care costs, schizophrenia symptom days, extrapyramidal symptom (EPS) days, suicide rates, and employment days are estimated. For each 1,000 people treated with typical drugs, the base case scenario gives estimates of annual medical care costs of $28.9 million with 80,253 moderate/severe schizophrenia symptom days and 92,006 EPS days. In the base case scenario, after switching to atypical drugs, schizophrenia symptom days are estimated to decrease up to 33 percent, EPS days up to 50 percent, and total medical care costs up to 19 percent over the 3-year period. Suicide rates fall and employment rates increase. The direction of the impacts remain the same for a wide range of input parameter values used in sensitivity analyses. Thus, switching to atypical drugs will likely reduce total medical care costs and decrease other disease burdens for people with schizophrenia, their families, and society.
Schizophrenia is a chronic mental illness often associated with repeated and prolonged admissions to the hospital. In addition, people with schizophrenia experience a significant economic and quality of life impact, as do their families and society at large (Rupp and Keith 1993) . The high use of the hospital is a key factor in the high costs of medical care for schizophrenia, which account for a significant share of the cost of mental health care in the United States Narrow et al. 1993; Rupp and Keith 1993) . Treatments that can reduce hospital admissions or the average length of stay in the hospital can result in significant cost savings. The second generation of antipsychotic drugs for treating schizophrenia-atypical drugs such as clozapine, risperidone, olanzapine, and quetiapine-effectively treat both positive and negative symptoms of the disease (Jibson and Tandon 1998) , and two, clozapine and olanzapine, have been shown to be effective in patients who are not responsive to or who are intolerant of the first generation, typical antipsychotic drugs such as haloperidol, chlorpromazine, or thioridazine (Tollefson et al. 2001) . But atypical drugs are considerably more expensive than typical drugs. Thus, it is important that decision makers have information to help them determine whether the safety and efficacy benefits are likely to result in greater value in terms of health care cost savings, and other population and societal benefits.
The standard method for estimating the population impacts of specific diseases is to use large observational data bases. Several studies using these data bases to examine the annual costs associated with schizophrenia have been published (Wyatt et al. 1995; Dickey et al. 1996; Rice and Miller 1996) . These studies present the total annual U.S. medical care costs for people with schizophrenia before the widespread introduction of atypical drugs. Such information is now becoming available for people treated with atypical drugs (Davies et al. 1998) . However, such studies give information on only costs-not individual health and family outcomes. In addition, in observational studies, people receiving the newer treatment might be systematically different from those receiving the older treatment. Also, such information is often not available at the time that medical policy makers have to decide whether to restrict access to the new treatment.
The advantage of developing a model-based approach to estimating the population impacts of a new treatment is that the comparison of treatment with the older drugs to treatment with the newer drugs can be made for different disease severity groups and for geographic areas with different treatment practice patterns or different unit costs. The model-based approach also allows for estimation of the impacts of the new treatment on individual and family outcomes not generally included in the observational data bases used in the studies cited above. Finally, with the model-based approach described in this article, preliminary estimates of the population impacts can be obtained before there is widespread use of the new treatment, and these estimates can be easily updated as more information becomes available.
A model has previously been described that estimates the burden of schizophrenia when treated with typical drugs (Mauskopf et al. 1999) . In this article, we extend this model to estimate the impact of switching from treatment with typical drugs to treatment with atypical drugs on the annual costs and individual and societal consequences in the U.S. schizophrenia population. The analysis takes a societal perspective because it includes estimates of a broad range of outcomes, including individual symptoms, medical care costs, employment rates, and social service costs. 
Methods
Model Overview. Figure 1 illustrates the structure of the population model for schizophrenia. The population comprises people with schizophrenia who present for treatment at any time during a 1-year time period and includes people with different categories of disease symptoms. Different treatments (which have different response, relapse, compliance, and side effects rates) can be chosen for each category of disease symptoms. The combination of disease symptoms and treatment choice determines the annual number of days with, and severity of, positive symptoms, negative symptoms, and drug side effects. The treatment choice and clinical outcomes then determine the annual health care service use and costs, and the individual, family, and societal burden for each category of disease symptoms. Health care services not associated with schizophrenia are not included in the model. The time horizon for the model is 3 years. 1. newly diagnosed during the year (newly diagnosed); 2. no acute or chronic psychotic episodes requiring hospitalization during the year (no episode); 3. one or more acute psychotic episodes during the year requiring short-term hospitalization, residential care, or both-these are people who are generally responsive to and tolerant of typical drugs and include "revolving door" patients (acute episode); 4. extended psychotic episodes during the year requiring prolonged hospitalization, residential care, or both but with some outpatient care during the year-these are people who are probably refractory to or intolerant of typical drugs (extended episode); and 5. institutionalized for the complete year-these are people who are probably refractory to or intolerant of typical drugs (institutionalized).
Symptom
For any 1-year time period, an individual can be classified in only one of these categories. While individuals may change category from year to year or even die, we take a prevalence-based perspective and assume that the number and proportion of schizophrenia patients in each category stay constant each year. The symptom category distribution for the general U.S. population is shown in table 1 and is estimated as follows. Based on estimates by Narrow et al. (1993) using data from the Epidemiologic Catchment Area Study, there are approximately 1.04 to 1.29 million people with schizophrenia symptoms in the United States who receive inpatient or outpatient care for their symptoms each year. Lieberman (1993) reported that 50,000 new cases arise annually, so newly diagnosed patients would account for approximately 4 to 5 percent of the prevalent schizophrenia population under treatment in a year. In this article, we assume that newly diagnosed individuals account for 4 percent of all people treated. An observational data study by Juarez-Reyes et al. (1995) estimated that 43 percent of people with schizophrenia would be denned as treatment refractory (experiencing prolonged or continuous episodes of symptoms) and thus be eligible for treatment with clozapine. We assume that 14 percent of the people who are refractory to or intolerant of typical drugs (6% of the total population) are institutionalized, based on baseline hospital data from a randomized, controlled effectiveness trial by Rosenheck et al. (1997) (% with hospital days > 180). The remaining 53 percent of the total population (100% -[4% + 43%]) are assumed to either experience one or more acute psychotic episodes or experience no psychotic episodes in a given year. We assume that 17 percent of this 53 percent (10% of the total population) have one or more acute episodes in the year (based on relapse rates of 17% for the first year after an episode in a prospective observational study by Conley et al. [1999] ). We assume that the rest do not have an episode requiring hospitalization that year (43% of the total population). Table 1 also presents two hypothetical symptom category distributions such as those that might be observed in a patient population treated at a state mental hospital (a more severely ill population) and in a patient population treated at a community mental health center (a less severely ill population). We use these distributions in sensitivity analyses. Tran et al. 1998 . 4 Chouinard et al. 1993 . 5 Rosenheck et al. 1997 . 6 Tollefson et al. 2001 . 7 Reidetal. 1994 . Gupta etal. 1997 Qlazer1998. 10 Meltzer and Okayli 1995. 11 Palmer etal. 1995. 12 Episode length is defined as 91.25 days. 13 Hutchins, unpublished data, 1999. In the model, treatment efficacy, symptom days, suicide rates, employment rates, and drug compliance are assumed to differ according to whether the population is treated with typical or atypical drugs but not according to which atypical drug is used. Among the different atypical drugs, only the dose, daily cost, and EPS rates are assumed to differ. Medical care use and costs, including inpatient and outpatient services and drugs, are also estimated for each disease symptom category (table 3) . The medical care use rates (other than drugs) vary depending on whether typical or atypical drugs are used but are the same for all atypical drugs. Costs per unit of medical care (except for drugs), such as the cost per acute hospital day, are held constant across treatments and disease symptom categories. A listing of the key data sources used and a summary of their characteristics (type of study, number of patients, location of study) and the parameters taken from each study are presented in an appendix. The derivation of each parameter value is described below and the values are shown in tables 2 and 3.
Health Outcomes and
Drug doses. We assume that all people treated with typical drugs receive a dose of 11.8 mg/day of oral haloperidol (Tollefson et al. 1997) for the acute episode, no episode, and newly diagnosed symptom categories, and a dose of 28 mg/day oral haloperidol (Rosenheck et al. 1997) or 150 mg/month of depot haloperidol decanoate (Glazer and Ereshefsky 1996) for the extended care and institutionalized symptom categories. For people treated with atypical drugs, we assume the following treatment patterns. For the acute episode, no episode, and newly diagnosed symptom categories we assume that, in any given year, 50 percent of patients are taking olanzapine (13.2 mg/day, Tollefson et al. 1997 ) and 50 percent are taking risperidone (5.6 mg/day, Conley et al. 1999) . For extended episode and institutionalized individuals, we assume that 33 percent are taking clozapine (304 mg/day, Tollefson et al. 2001) , 33 percent are taking risperidone (5.6 mg/day, Conley et al. 1999) , and 33 percent are taking olanzapine (21 mg/day, Tollefson et al. 2001) .
EPS rates. EPS rates, which are based on reports from clinical trials, represent the percentage of individuals needing to take antiparkinsonian drugs or other drugs to treat the EPS while they are taking antipsychotic drugs. The rates are 48 percent for haloperidol (Tran et al. 1998) , 17 percent for olanzapine (Tran et al. 1998) , and 29 percent for risperidone for the acute episode(s), no episode, and newly diagnosed symptom categories. The rates are 67 percent for haloperidol , 10 percent for clozapine , 29 percent for risperidone , and 17 percent for olanzapine (Tran et al. 1998) for the extended episode and institutionalized symptom categories. The cost per day with EPS of $0.54 was taken from an estimate in a modeling study by Glazer and Ereshefsky (1996) that included both monitoring and benztropine costs.
Response and relapse rates. Response and relapse rates were taken from clinical trials and observational data. In our model, we assume that people in the acute episode(s) symptom category are equally responsive to typical and atypical drugs. There is no difference in this efficacy measure. However, the relapse rates for people in the acute episode(s) symptom category differ by drug type. We assume a 1-year relapse rate of 28 percent for typical drugs and of 19.7 percent for atypical drugs (a reduction of 30% compared with the typical drugs) based on a meta-analysis of relapse rates for responsive patients from three olanzapine versus haloperidol randomized, controlled clinical trials (Tran et al. 1998) . Response rates for the extended episode and institutionalized symptom categories are assumed to be 60 percent for the atypical drugs, based on a randomized, controlled clinical trial comparing clozapine and olanzapine (Tollefson et al. 2001 ). Similar response rates have been observed for the atypical drugs in other clinical trials (Kane et al. 1988; Owen et al. 1989; Kleiser et al. 1995) . The relapse and response rates for the newly diagnosed symptom category for the typical drugs were taken from an observational study by Gupta et al. (1997) . With treatment with atypical drugs, we assume that the percentage of newly diagnosed individuals who experience an extended episode in the year of diagnosis is reduced by 60 percent and the relapse rate for those experiencing acute episode(s) is 30 percent lower than for those treated with typical drugs.
Moderate or severe symptom days. Days with moderate or severe symptoms are defined in our analysis as days with a Brief Psychiatric Rating Scale score greater than 36 (Overall and Gorham 1962; Tollefson et al. 2001) . Moderate or severe symptom days are assumed to be:
• 0 for people not experiencing an episode requiring hospitalization; • 60 days for each acute episode in newly diagnosed individuals experiencing acute episodes (Gupta et al. 1997 ); • 42 days for each acute episode in subsequent years (Tollefson et al. 1997) ; and • equal to the number of days in the hospital or other residential care facility for newly diagnosed individuals with extended episodes, extended episode and institutionalized individuals.
Working months. Working months are measured as the product of employment rate and months of employment. The data sources for the employment rate are limited, and thus our estimates are speculative. For newly diagnosed individuals, Gupta et al. (1997) found that 49 percent of first episode patients were unemployed during the year. We assume that the people who are employed work for the entire period that they are not hospitalized, which is 9.6 months for people treated with typical drugs and 10.0 months for people treated with atypical drugs. A randomized trial (Tollefson et al. 1997) found that 8.4 percent of people treated with haloperidol and 19.4 percent of people treated with olanzapine had some productive work activity in the 45 weeks after a 7-week acute treatment period (reported in Glazer 1998). We assume these rates of employment for people in the acute episode(s) symptom category on typical and atypical drugs, respectively. Of those people who work, we assume that people treated with typical drugs work for 10.2 months and that people treated with atypical drugs work for 10.3 months, computed as the number of months without moderate or severe symptoms. We also assume the same 8.4 percent and 19.4 percent employment rates throughout the year for people in the no episode symptom category who are treated with typical and atypical drugs, respectively. People who need extended care or are institutionalized when taking typical drugs are assumed not to work at all (Davies and Drummond 1994) . However, in their second and third year of treatment, those extended episode individuals who are responsive to atypical drugs are assumed to work at the same rate as individuals in the acute episode(s) symptom category on atypical therapy. Institutionalized individuals in their third year of treatment who are responsive to atypical therapy are assumed to work at the same rate as individuals in the acute episode(s) symptom category on atypical drugs. Suicide rates. We identified rates of suicide attempts for people treated with typical drugs for the acute episode(s) symptom category (13.1% per episode) and for the extended episode or institutionalized symptom categories (8.5% per year) from an observational study by Meltzer and Okayli (1995) . Suicide attempt rates may decline later in the disease (Black 1988) . However, the Meltzer and Okayli (1995) estimates were for people within 10 years of diagnosis. Because of this, we halved their rates to 6.55 percent per episode for the acute episode symptom category and 4.5 percent per episode for the extended care or institutionalized symptom categories. We made this adjustment to account for the fact that most schizophrenia populations will include people who have had the disease for up to 30 years or more. Suicide attempt rates for newly diagnosed individuals were taken from an observational study by Cohen et al. (1994) . This study found a suicide attempt rate of 18 percent among first admissions. We assume that the proportion of completions to attempts is the same as that in the general U.S. suicide population-23 percent (Palmer et al. 1995) . The costs per suicide attempt and completion were estimated using data from Palmer et al. (1995) . For the newly diagnosed and acute episode symptom categories, suicide attempt rates with atypical drugs are estimated to be lower than suicide attempt rates for typical drugs based on the lower rates of relapse episodes in a year. For extended episode and institutionalized individuals who were responsive to atypical drugs, the suicide attempt rates are estimated to be 43 percent of the rates with typical drugs, based on data from a randomized clinical trial (Tollefson et al. 1997) as reported by Glazer (1998) .
Drug compliance rates. We use compliance rate (defined as the number of days taking the antipsychotic drug divided by the number of days since the initial prescription) as a proxy measure for overall drug efficacy and impact on the family and on the criminal justice system. Several studies have shown that these outcomes are associated with compliance rate (McFarland et al. 1989; Robinson et al. 1999) . Data on compliance rates are limited, and thus our estimates are speculative. Compliance rates were approximated based on data from a clinical trial (Tran et al. 1998 ) and on data taken from an observational study of persistence with antipsychotic therapy (Hutchins, unpublished data, 1999) . The compliance rate for acute episode individuals (who are assumed to be responsive to and generally tolerant of drug therapy) during the year with an episode is assumed to be 85 percent with both typical and atypical drugs (based on clinical trial data) (Tran et al. 1998 ). The compliance rate for people in the extended episode and institutionalized categories while in inpatient care is assumed to be 100 percent. Outpatient compliance for people with an extended episode taking typical drugs is assumed to be 30 percent. This is a weighted average (75% oral therapy and 25% depot therapy) of the compliance rate with typical oral therapy (average value at 180 and 360 days after starting oral therapy from the observational data base [13. 3%, Hutchins, unpublished data, 1999] ) and the assumed compliance rate with depot therapy from the Glazer et al. model (80%, Glazer and Ereshefsky 1996) . When people in the extended episode or institutionalized categories are responsive to atypical drugs and are in outpatient care, the compliance rate is assumed to be 47 percent. This is the average compliance with atypical therapy at 180 and 360 days after starting therapy from the observational data base (28.2%, Hutchins, unpublished data, 1999) divided by 0.6 to account for the 40 percent of nonresponders who discontinue using atypical drugs before 180 days because of lack of efficacy. The compliance rate for people in the no episode category for typical (10%) and atypical (22%) drugs is the average of the compliance rates for these types of drugs at 360 and 731 days after starting therapy in the observational data base (Hutchins, unpublished data, 1999) . The observational data base included all users of the medications, not just those with a diagnosis of schizophrenia; the resulting statistics, which include less chronic or more incidental uses of the drugs, may underestimate compliance within schizophrenia.
Medical care use and costs. Health care costs for each individual in each symptom category were calculated using estimates of the unit costs for each health care service and estimates of the health care services used by each individual. Table 3 presents the unit cost estimates, average annual units used, and total cost per individual treated over the 3-year time horizon for each symptom category and each medication treatment choice. The health care use and unit cost estimates are derived primarily from three published sources:
1. an observational study by Gupta et al. (1997) for people who are newly diagnosed; 2. a modeling study by Palmer et al. (1998) for people experiencing no episode and people experiencing acute episodes; and 3. a randomized, controlled effectiveness study by Rosenheck et al. (1997) for people who are experiencing an extended episode or who are institutionalized.
The drug costs were taken from the 1999 Red Book (1999) estimates of average wholesale price. Resource use and cost estimates for the newly diagnosed and acute episode individuals are a function of the number of annual episodes. Estimates for newly diagnosed individuals are based on estimates by Gupta et al. (1997) of an acute relapse rate of 43.6 percent with typical antipsychotic drugs (30.7% with atypical drugs based on a 30% reduction in relapse rate) and a chronic relapse rate of 5.4 percent with typical drugs (2.2% with atypical drugs based on a 60% reduction in lack of response). Estimates for those with an acute episode are based on clinical trial estimates by Tran et al. (1998) of a relapse rate of 28 percent within the same year with typical drugs and 19.8 percent per year with atypical drugs. For people in the extended episode and institutionalized categories who respond to atypical drugs, we assume inpatient resource use of 77 percent, 55 percent, and 43 percent compared with that used by patients taking typical drugs for years 1, 2, and 3, respectively. These relative values are based on the Rosenheck et al. clinical trial for year 1 (1997) and the Reid et al. observational data study for people who respond to clozapine for years 2 and 3 (1994) . A ratio of residential home care to total inpatient care of 54 percent was assumed for all extended episode individuals and for institutionalized individuals who are responsive to atypical drugs. This ratio was calculated using Rosenheck's data for inpatient stay for haloperidol-treated patients, assuming that the average number of hospital days in the year before the study remained unchanged during the study year. For outpatient services for extended episode individuals responsive to atypical drugs, we assume a relative use rate of 1.8 compared to those on typical drugs for the 3 years after switching from typical drugs, based on the Rosenheck study (1997) .
Social services. The annual costs for two social service programs were taken from the published literature. The annual cost for the assertive community treatment (ACT) program is $6,993 (Clark et al. 1998b) , and the annual cost for a work support (WS) program is $3,757 (Clark et al. 1998a ). To make these programs comparable to other ambulatory services, we assume a service unit cost of $43 (the same as a group therapy session) and use the annual costs to compute an average annual number of service units (163 for ACT and 87 for WS). There are few data on the proportion of people with schizophrenia who use either or both of these programs. Usage rates depend on individual characteristics as well as program availability. We have made a series of assumptions to include in the model's base case, but these numbers do not have a sound basis in the published literature. Therefore, these numbers should be updated as more data become available.
We assume that newly diagnosed individuals treated with typical or atypical drugs do not use ACT or WS services. We assume that 20 percent of the people in the acute and no episode symptom categories use both types of services when treated with typical drugs, and that 26 percent use both types of services when treated with atypical drugs (except during time periods when they are experiencing moderate or severe psychotic symptoms). This difference is based on the assumption that people who experience fewer negative symptoms may be more likely to use these services if given the option (Weiden et al. 1996) . We assume that extended episode and institutionalized individuals do not use either ACT or WS services when treated with typical drugs, or when they are nonresponsive to atypical drugs. For extended episode individuals who are responsive to atypical drugs, we assume service use rates while they are not hospitalized of:
• 10 percent ACT and 0 percent WS in year 1; 26 percent ACT and 13 percent WS in year 2; and • 26 percent ACT and 26 percent WS in year 3.
For institutionalized patients who are responsive to atypical drugs, we assume service use rates while they are not hospitalized of:
• 0 percent ACT and WS in year 1; • 10 percent ACT and 0 percent WS in year 2; and • 26 percent ACT and 13 percent WS in year 3.
Analyses-Base Case and Sensitivity Analyses.
The base case analysis compares the use of typical drugs and the use of atypical drugs for 1,000 people with schizophrenia with a distribution of disease symptom categories similar to that of the U.S. population. Annual costs and individual and proxy outcomes are estimated. For the sensitivity analyses, we determine the impact of changes in the following input parameter values on the outcomes:
• distribution of disease symptom categories within the schizophrenia population (e.g., for state mental hospital or community mental health center populations);
• impact of change to atypical drugs on "revolving door" individuals (defined as people experiencing two acute episodes in a single year); • upper and lower bounds for differences in antipsychotic drug relapse and response rates; • average daily costs for inpatient residential care; • average daily costs for atypical drugs; and • impact of change to atypical drugs on Medi-Cal expenditures for people with schizophrenia.
Results
Figure 2 presents the impact of switching to atypical drugs on total medical care costs and different cost subcategories for 1,000 people with schizophrenia. In year 1, a decrease in hospital and residential care costs is offset by an increase in medication and outpatient costs, producing a net decrease of 1 percent compared with treatment with typical drugs. In years 2 and 3, following the switch to atypical drugs, the drug and outpatient costs remain fairly constant, while the state mental hospital and residential care costs continue to decline. The result is decreases in total medical costs of 13 percent (year 2) and 19 percent (year 3), relative to costs under treatment with typical drugs. Table 4 presents the impact of switching to atypical drugs on costs as well as on other individual patient outcomes. Relative to treatment with typical drugs, EPS days are 45 percent lower in year 1 and 41 percent lower in year 3. The number of moderate to severe symptom days is 13 percent lower in year 1 and 33 percent lower in year 3. Suicides are reduced by 21 percent, compliance is increased by 12 percent to 21 percent, and inpatient days are reduced 13 percent in year 1 to 33 percent in year 3. Costs for social services such as vocational rehabilitation are increased by 43 percent in year 1 to 86 percent in year 3, as people leave inpatient settings and are able to benefit from these services. Employed months increase by 106 percent in year 1 to 180 percent in year 3. Table 5 presents the results of the sensitivity analysis. The impacts of changes in the parameter values are shown for years 1 and 3 only. The impacts are shown for total medical care cost, EPS days, and moderate/severe symptom days as representative of societal and patient outcomes. Under most of our assumptions about drug use patterns and unit costs, EPS days and moderate/severe symptom days decrease as more people are treated with atypical drugs. However, because of higher compliance rates expected for people with no episode in a given year taking atypical agents, EPS days could be slightly higher in this subgroup if people are treated with atypical drugs, depending on the drug used and the dose prescribed. Reductions in moderate/severe symptom days are sensitive to the disease severity of the treated population as well as -42,173 -10,938 -7,251,770 -38,561 -26,447 -74,636 -23,057 -17,742,320 -66,232 -59,146 -51,814 -10,098 -5,836,770 -48,543 -23,207 -77,563 -12,432 -4,815,464 -77,563 -12,432 -42,173 -10,938 -5,258,768 -38,561 -26,447 -42,173 -10,938 -7,728,290 -38,561 -26,447 -42,173 -10,938 -6,775,254 -38,561 -26,447 -42,791 -8,585 -5,449,596 -36,162 -21,508 -50,197 -13,202 -8,646,440 -46,887 -31,295 -35,451 -5,799 -3,234,826 -25,607 -13,553 -17,146 -3,304 903,132 -15,904 -7,854 Note.-A = difference; EPS = extrapyramidal symptoms. 1 Assuming 86% extended episode and 14% institutionalized. 2 Assuming 5% newty diagnosed, 25% no episode, 25% acute episode, 45% extended episode, and 0% institutionalized. 3 Lower 95% confidence limit for relapse rate for typical drugs for acute episode individuals and for response rate for extended episode and institutionalized individuals for atypical drugs and upper 95% confidence limit for relapse rate for atypical drugs for acute episode individuals. 4 Upper 95% confidence limit for relapse rate for typical drugs for acute episode individuals and for response rate for extended episode and institutionalized individuals for atypical drugs and lower 95% confidence limit for relapse rate for atypical drugs for acute episode individuals. 5 Assuming a 30% response rate for extended care and institutionalized individuals to atypical drugs. 6 Assuming population distributed as follows: 80.9% no episode, 11.4% acute episode, 3.1% extended episode, and 4.6% institutionalized; no payment for psychiatric hospital days, average payment of $50/day in acute hospital and of $80/day in nursing home (because of first payment by Medicare in many cases); and average length of stay in the hospital for an acute episode of 8 days-data from 1994 Medi-Cal payment records.
to our assumptions about the comparative efficacy of the typical and atypical drugs. Our model does not currently distinguish between mild and no symptom days; therefore, it does not capture symptom improvements that less severely ill people may experience. Given our base case assumptions, total medical care costs are similar under treatment with typical or atypical drugs in year 1. The direction of the medical cost difference in that first year is sensitive to several input parameters. In particular, under treatment with atypical drugs, year 1 total medical costs may be lower if the population is more seriously ill, if atypical drugs prices are lower, or if the response rate for extended episode and institutionalized individuals is higher. Conversely, year 1 total medical costs may be higher under treatment with atypical drugs if those input parameters are shifted in the opposite direction. However, the finding of lower total medical costs for year 3 under atypical rather than typical drug treatment is robust; those costs are lower for the wide range of input parameter values tested, as shown in table 5. The one exception is for the sensitivity analysis run to estimate changes in Medi-Cal expenditures when switching treatment from typical drugs to atypical drugs, which indicated that Medi-Cal costs for year 3 with atypical drugs would still be higher than for typical drugs in year 3.
Discussion
The model base case estimates indicate that switching people from typical drugs to atypical drugs will improve individual and family well-being with decreased medical care costs and increased social service costs. Although the cost and outcome estimates are sensitive to input parameter assumptions, for a wide variety of parameter values, medical care costs were shown to decrease by the third year after switching to atypical drugs. The one exception is the scenario run estimating Medi-Cal expenditures for people with schizophrenia. The main reason for the difference in results using this scenario is that Medi-Cal does not pay for all of the costs of treating people with schizophrenia. Payments for hospitalizations at psychiatric facilities are reimbursed through not Medi-Cal but other public funds. There is also a substantial portion of people with schizophrenia whose disabled status qualifies them for both Medicare and Medi-Cal, in which case Medicare is the primary payer for hospital and physician services, while Medi-Cal pays for medications. The Medi-Cal scenario may also overestimate the portion of the population with no episode, as some psychiatric hospitalizations may not be captured in the data. Thus, the Medi-Cal scenario omits much of the savings in public funds that may result from fewer hospitalizations among those using atypical antipsychotics. The Medi-Cal scenario might also underestimate the reductions in symptom and EPS days in their population. This result illustrates the importance of looking at the total costs associated with treatment of schizophrenia rather than taking the perspective of a single payer.
A key value of the interactive computer model used to generate these results is that the input parameter values can readily be altered to reflect a specific schizophrenia population as well as regional patterns of care and unit costs. Thus, the outcomes of a switch from typical to atypical drugs can be estimated for the population of interest.
It is very important to develop methods that extrapolate from clinical trial data to the population for which a decision maker may be responsible. In this article, we have assumed that the efficacy rates shown in clinical trial and observational study populations are the same as would be observed in normal practice for people with characteristics similar to those of the people enrolled in the trials. In addition, we have extrapolated from the types of people typically enrolled in clinical trials to the more general population using data from epidemiological studies of schizophrenia to determine the actual symptom profile. For example, clinical trials of new schizophrenia drugs often enroll only people who are experiencing moderate or severe psychotic symptoms requiring hospitalization. A large proportion of the schizophrenia population will not experience such severe symptoms in any given 1-year time period. If people with no episodes are switched to atypical antipsychotics, they will likely experience an increase in drug costs, a reduction in negative symptoms, and a reduction in EPS days. In our analysis, we have been conservative and have assumed that there are no health care cost savings or quality of life gains (e.g., fewer negative symptoms) for the no episode individuals switched to atypical drugs (apart from fewer days needing EPS drugs).
Our model also illustrates the importance of the time horizon chosen. Although what happens in the first year that a new drug is introduced is important to decision makers, the full impact of switching to a new therapy for a long-term illness such as schizophrenia may not be felt for many years. We chose a 3-year time horizon for this model because there are published data indicating that health care use continues to fall for up to 3 years for extended episode and institutionalized individuals who respond to an atypical drug (Reid et al. 1994) . Other possible impacts of more tolerable or effective therapy might be an increase in the proportion of the population who experience no episodes during a given year or a reduction in the proportion of newly diagnosed individuals who go on to experience extended episodes or to be institutionalized. Over time, these impacts would reduce the proportion of acute episode, extended episode, or institutionalized individuals in the prevalent population. Our model could be used to estimate the individual, family, and societal outcomes associated with such impacts. We have not estimated these outcomes in this article because there are currently no data to demonstrate whether such effects occur and what their magnitude might be. Also, these impacts would not become important drivers of the total cost and health burdens for a schizophrenia population until several years after the introduction of the new drugs.
An important issue that has to be addressed when developing models of the impact of new drugs is the conflict between the decision makers' need for more detailed information and the availability of experimental or observational data to support those estimates. The relapse and response rate data used in this study were taken from randomized, controlled efficacy or effectiveness trials (Rosenheck et al. 1997; Beasley et al. 1998; Tran et al. 1998) . However, when we first presented the model to decision makers, they expressed the need to have estimates of inpatient care broken out by type of inpatient care (e.g., into acute hospital, state hospital, and nursing home or other residential care facility). The problem was that these data were not presented at this level of detail in the published literature for the extended episode and institutionalized individuals. To produce the estimates of this breakdown, we developed the algorithm described in the Methods section. The decision makers also wanted information on the use of social services by people with schizophrenia and how this might change with the introduction of atypical agents. There were no studies that indicated the current magnitude of use-we used a verbal estimate from National Alliance for the Mentally 111 personnel-and there were only anecdotal data that indicated an increase in use of these services by patients taking atypical drugs. Thus, the modeler faces a dilemma when the data are not sufficient to give the decision maker the information at the necessary level of detail. Our solution was to make all of our assumptions clear and allow them to be easily changed in an interactive computer model. This method allows the assumptions to be updated as more data become available.
Developing models to estimate the annual burden of an illness with and without use of a new therapy can provide important information when a decision must be made about the use of the new therapy. Previous studies of the burden of schizophrenia have taken a retrospective look at large U.S. data bases to derive the estimates (Wyatt et al. 1995; Dickey et al. 19%; Rice and Miller 19%) . While retrospective studies estimate actual costs incurred, they cannot estimate the impact of new treatments in a timely manner. Once the new treatments have been widely used for several years (allowing 
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